NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
Clinical Trials
4,973 trialsNCT02960087 2026-04-22
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
Canadian Cancer Trials Group
Phase NA Active not recruiting
NCT03181867 2026-04-22
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03436654 2026-04-22
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03866382 2026-04-22
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04530552 2026-04-22
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05155501 2026-04-22
PARTIAL
Weill Medical College of Cornell University
Phase NA Recruiting
NCT06172283 2026-04-22
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
State University of New York at Buffalo
Phase NA Recruiting
NCT06257264 2026-04-22
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06785636 2026-04-22
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT07332455 2026-04-22
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
GlaxoSmithKline
Phase 1/2 Recruiting
NCT07545811 2026-04-22
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics
Phase 1 Recruiting
NCT02759744 2026-04-21
Fusion Guided Focal Laser Ablation of Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase NA Enrolling by invitation
NCT04523207 2026-04-21
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Janssen Research & Development, LLC
Phase 2 Completed
NCT04946370 2026-04-21
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT06136650 2026-04-21
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06651632 2026-04-21
WATER IV PCa
PROCEPT BioRobotics
Phase NA Recruiting
NCT06952803 2026-04-21
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT07047118 2026-04-21
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT07407283 2026-04-21
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT07541066 2026-04-21
Robotic Telesurgery in Urology
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT07541911 2026-04-21
LaserSAFE
University College, London
Phase NA Not yet recruiting
NCT07542379 2026-04-21
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07543055 2026-04-21
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
Phase 1 Not yet recruiting
NCT05800665 2026-04-20
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT06465069 2026-04-20
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT06551324 2026-04-20
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06925737 2026-04-20
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07126548 2026-04-20
A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
Mayo Clinic
Phase NA Not yet recruiting
NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT00951535 2026-04-17
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT04071236 2026-04-17
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05022849 2026-04-17
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
NCT06610474 2026-04-17
Evaluation of an Online Prostate Cancer Screening Decision Aid
Centers for Disease Control and Prevention
Phase NA Completed
NCT07114601 2026-04-17
OMNIRAY
Eli Lilly and Company
Phase 1 Recruiting
NCT07234981 2026-04-17
PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT07253987 2026-04-17
SURV-QoL
Masaryk Memorial Cancer Institute
Phase NA Recruiting
NCT07468708 2026-04-17
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07535541 2026-04-17
BioWEAR
University of Virginia
Phase NA Not yet recruiting
NCT07535905 2026-04-17
REVIVE
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT05616650 2026-04-16
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06171139 2026-04-16
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
University of California, San Francisco
Phase NA Recruiting
NCT06347705 2026-04-16
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06439225 2026-04-16
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06451614 2026-04-16
HYDROSPACE
Boston Scientific Corporation
Phase NA Active not recruiting